entertainment -WSS

entertainment

author：explore 2025-09-28 01:34:51 - browse：47

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How to convince healthy people to buy insurance

focus

WSS

How climate

After Sarepta trial failure, Duchenne families brace for more debate

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

STAT Summit: Biotech founders on deal

How neuroscience research could help beat back brain cancer

STAT Summit: Biotech founders on deal

Wikipedia

entertainment

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Lawmakers consider Medicare pay reforms for doctors

Dobbs anniversary: the lost opportunity of abortion as health care

Senate committee scrutinizes Medicare Advantage brokers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Travis Kelce and the trap of celebrity vaccine endorsements

As demand for Covid shots wanes, Moderna seeks its next success

FDA struggles to regulate food additives, sometimes for decades

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gene therapy’s promise and the high cost of hope

hotspot

UnitedHealth’s board chair also owns a personal investment firm

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Medicare reduced heart disease by changing how it pays doctors

HHS leader on health, climate change and biopharma emissions

What is microchimerism and how does it affect maternal health?

How to convince healthy people to buy insurance

focus

hotspot

focus

explore